Principles of UFMylation-driven antibacterial defence
The status, timeline and source of this project. A free account opens every field.
Source: EU Funding & Tenders Portal
Shigella is a Gram-negative bacterium that causes bacillary dysentery, killing around 200 thousand people each year and representing an urgent global threat due to rising antibiotic resistance. Beyond its medical relevance, Shigella has long been a paradigm in cellular microbiology, yielding landmark insights into host–pathogen interactions and illuminating fundamental mechanisms in cell biology.
- Status
- Prospective
- Sector
- Hospital
- Location
- Switzerland
- Updated
- 19 Nov 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Principles of UFMylation-driven antibacterial defence
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | forthcoming |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | Shigella is a Gram-negative bacterium that causes bacillary dysentery, killing around 200 thousand people each year and representing an urgent global threat due to rising antibiotic resistance. Beyond its medical relevance, Shigella has long been a paradigm in cellular microbiology, yielding landmark insights into host–pathogen interactions and illuminating fundamental mechanisms in cell biology. In my recent work, I discovered that UFMylation—a ubiquitin-like protein modification pathway with established roles in cell homeostasis—functions as a novel antibacterial defence mechanism. UFMylation marks intracellular bacteria such as Shigella for elimination, in a process independent from canonical ubiquitylation and autophagy, thereby uncovering an unexpected and largely unexplored branch of host immunity. The proposed project will elucidate the fundamental mechanisms of antibacterial UFMylation, revealing novel molecular principles of host recognition of intracellular bacteria, downstream pathways driving microbial elimination, and sophisticated pathogen evasion strategies. I will further investigate how these molecular events intersect, compete and ultimately impact UFMylation-mediated homeostasis at the cellular and tissue levels, repositioning this pathway at the interface between host defence and physiology. Through the integration of in vitro reconstitution systems, cellular assays and organoid models, and leveraging the powerful molecular toolkit of Shigella, this project is uniquely positioned to deliver breakthrough discoveries in the field of host-pathogen interactions and cell biology. Advancing our fundamental understanding of UFMylation may inspire innovative therapeutic strategies against antimicrobial-resistant infections, while also informing pathological conditions associated with UFMylation, such as cancer, inflammation, and Alzheimer’s disease. |
Location
Country | Switzerland |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Hospital |
Article published date | 2026-10-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Hospital projects in Switzerland
- AGORA Cancer Centre, Lausanne
- SUN2CHEM
- BIOVERSYS (COVID-19) (IDFF)
- Helsinn New Cytotoxic Plant, Biasca
- Merck Biotech Development Facility, Corsier-sur-Vevey, Switzerland
- Thermo Fisher Scientific’s Biologics Manufacturing Facility, Lengnau, Switzerland
- Caring for and improving the quality of life of terminal patients and their families
- Development of an accurate and reliable innovative solution for tumour destruction in interventional radiology
